SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Cell Therapeutics (CTIC)
An SI Board Since August 1997
Posts SubjectMarks Bans Symbol
946 45 0 CTIC
Emcee:  Regis McConnell Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
471>Say that 100% of the drug was excreted as the active form. Would that be betformer_pgs-2/24/2005
470From my reading, Taxol is effective at concentrations that are well below 1 uM. former_pgs-2/24/2005
469<i>If I'm correctly reading Miljenko's original comment (valuationClarksterh-2/24/2005
468> That leaves the remaining 10-20% of the dose to do the heavy lifting That CrazyPete-2/24/2005
467<i>the fact that an inactive prodrug is largely excreted as an inactive przeta1961-2/24/2005
466no messagezeta1961-2/24/2005
465In Message 20932102 , MJ says, "My memory on 2103 PK is going back to 2000Ian@SI-2/24/2005
464If I'm correctly reading Miljenko's original comment (valuation thread #former_pgs-2/24/2005
463It's also a study that no one here has seen! Was it a safety trial in healtIan@SI-2/24/2005
462> If 75% of the dose of Xyotax excreted unchanged, that means > that you CrazyPete-2/24/2005
461>> a somewhat restricted diffusion mechanism << one big passive bagscaram(o)uche-2/24/2005
460Thank you. That is clear, and makes more sense to me if the excretion of unmetabquidditch-2/24/2005
459>Why is there, necessarily, an inconsistency between the theory advanced by Cformer_pgs-2/24/2005
458Couldn't the public results to date also be consistent with excellent efficaIan@SI-2/24/2005
457f_pgs, confused: As to (2): "I find this to be the relatively <b>unlquidditch-2/24/2005
456re: PK/PD for Xyotax I caught that post stating that a great fraction (>75%?former_pgs-2/24/2005
455>>Wonder if there was anything compelling earlier in the pipe that they goIcebrg-2/24/2005
454Thanks..I was hoping that the PK/PD data could be clarified from this paper..as zeta1961-2/24/2005
453Of course, it's old news. But the issue wasn't quite resolved to my sattuck-2/24/2005
452Thanks, Peter. And the fact that so many of the patients in the multi-center trquidditch-2/23/2005
451It's basically a comparison of survival - not much room for argument on survBiomaven-2/23/2005
450Peter, on that score--top line data--could you review briefly the primary endpoiquidditch-2/23/2005
449Zeta, I think it was pretty much mostly old news. Or even if it wasn't, at Biomaven-2/23/2005
448Since nobody posted anything here about the recent Xyotax paper referenced in Tuzeta1961-2/23/2005
447Cross posting a couple of CTIC related posts from the Valuation thread . . . tuck-2/22/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News